The RNA therapeutics industry is poised for a transformative 2026, driven by groundbreaking technological advancements, expanding clinical applications, and a rapidly growing pipeline of innovative therapies. Following the remarkable success of mRNA-based COVID-19 vaccines, the field has seen a surge in investment and research aimed at unlocking RNA's potential for a wide range of therapeutic uses. From targeted cancer treatments to ex vivo gene therapies for rare genetic disorders, the RNA therapeutics sector is experiencing exciting developments that continue to gain momentum. ‍ Southeast Asia, including Thailand and Singapore, is leading RNA drug development. SSCG Cell Therapy has teamed up with A*STAR to create labs for cellular immunotherapies, while Arcturus Therapeutics, in partnership with Vinbiocare, is conducting clinical trials for ARCT-154, an mRNA vaccine targeting COVID-19 variants. With approvals in Singapore and Vietnam, the region is becoming a key player in mRNA vaccine tech. Advancements in RNA delivery, modification, and manufacturing are driving broader adoption and commercialization, improving the precision of RNA treatments and opening doors for personalized medicine and gene therapies. ‍RNA Therapeutics and Manufacturing Asia 2026 will bring together experts, researchers, and industry leaders to explore the latest trends in RNA therapeutics and manufacturing. Discussions will cover mRNA, RNA interference (RNAi), antisense oligonucleotides, scalable manufacturing solutions, optimizing RNA synthesis, purification, and quality control, while exploring cost-effective, high-yield production technologies. With Asia emerging as a key hub for RNA innovation, this conference offers a vital platform for professionals to share insights, tackle challenges, and drive the future of RNA-based therapies.

‍